Hasil Pencarian - L. Griškevicius

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    P592: GILTERITINIB IN COMBINATION WITH VENETOCLAX, LOW DOSE CYTARABINE AND ACTINOMYCIN D FOR FLT3 MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

    P592: GILTERITINIB IN COMBINATION WITH VENETOCLAX, LOW DOSE CYTARABINE AND ACTINOMYCIN D FOR FLT3 MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA oleh A. Žučenka, R. Pileckytė, K. Maneikis, V. Vaitekėnaitė, L. Kevličius, L. Griškevičius

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    PB2115: TRIAL IN PROGRESS: A RANDOMIZED PHASE II STUDY OF MB-CART2019.1 COMPARED TO STANDARD OF CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION

    PB2115: TRIAL IN PROGRESS: A RANDOMIZED PHASE II STUDY OF MB-CART2019.1 COMPARED TO STANDARD OF CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR AUTOLOGOUS ST... oleh P. Borchmann, P. Vandenberghe, A. Urbano, C. Haioun, F. Lemonnier, L. Griškevicius, S. Maury, S. Holtkamp, B. Friedrichs, G. Zadoyan, L. Hanssens, C. Brillant, U. Bethke, M. Assenmacher, I. Bürger, B. Philippe, T. Overstijns, U. Jäger, M. J. Kersten

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    S238: MATCHED RELATED VERSUS UNRELATED VERSUS HAPLOIDENTICAL DONORS FOR ALLOGENEIC TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST COMPLETE REMISSION AFTER TWO INDUCTION COURSES: A STUDY FROM THE ALWP/EBMT

    S238: MATCHED RELATED VERSUS UNRELATED VERSUS HAPLOIDENTICAL DONORS FOR ALLOGENEIC TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST COMPLETE REMISSION AFTER TWO INDUCTION COURSES: A... oleh A. Nagler, M. Labopin, S. Mielke, J. Passweg, D. Blaise, T. Gedde-Dahl, J. J. Cornelissen, U. Salmenniemi, I. Yakoub-Agha, P. Reményi, G. Socié, G. Van Gorkom, H. Labussière-Wallet, X.-J. Huang, M. Thérèse Rubio, J. L Byrne, C. Craddock, L. Griskevicius, F. Ciceri, M. Mohty

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG

    S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP,... oleh M. Lübbert, P. Wijermans, M. Kicinski, S. Chantepie, W. van der Velden, R. Noppeney, L. Griskevicius, A. Neubauer, M. Crysandt, R. Vrhovac, M. Luppi, S. Fuhrmann, E. Audisio, A. Candoni, O. Legrand, R. Foà, G. Gaidano, D. van Lammeren-Venema, E. F. Posthuma, M. Hoogendoorn, A. Giraut, M. Stevens-Kroef, J. H. Jansen, E. Ammatuna, J.-P. Vilque, R. Wäsch, H. Becker, N. Blijlevens, U. Dührsen, F. Baron, S. Suciu, S. Amadori, A. Venditti, G. Huls

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: